104 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
Rheinische Friedrich-Wilhelms-Universit£T Bonn
New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
University of Lyon 1
Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity.
University Bayreuth
The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
University of Bonn
Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
University of Bonn
Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.
University of Regensburg
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
The Hong Kong Polytechnic University
Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
Chinese Academy of Sciences
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Glaxosmithkline
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
University of Bonn
Thieno[2,3-b]pyridines--a new class of multidrug resistance (MDR) modulators.
Institute of Organic Synthesis
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Novartis Institutes For Biomedical Research
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Bmssi Umr 5086 Cnrs/Universit£
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Bmssi Umr 5086 Cnrs/Universit£
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
University of Bonn
Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
University of Bonn
Activity-lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments.
University of Bari Aldo Moro
Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.
University of Bari Aldo Moro
Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters.
University of Bari Aldo Moro
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
University of Regensburg
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
St. Jude Children'S Research Hospital
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
The Netherlands Cancer Institute
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
Hungarian Academy of Sciences
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Membrane Research Group of The Hungarian Academy of Sciences
Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Hospital For Sick Children
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
University of Washington
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
Japanese Foundation For Cancer Research
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
University of Bonn
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Uppsala University
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
Bmssi Umr 5086 Cnrs/Universit£
Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
Gilead Sciences
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Cnrs/Universit£
Inhibition of ABCG2-mediated drug efflux by naphthopyrones from marine crinoids.
Nci-Frederick
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
University of Regensburg
Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
Universita Degli Studi Di Bari
Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
Umr 5063 Cnrs/Universit£
Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors.
Umr 5086 Cnrs/Universit£
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
University of Bonn
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).
Universidad Nacional De Colombia
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.
National Cancer Institute-Frederick
Interaction potential of etravirine with drug transporters assessed in vitro.
University Hospital Heidelberg
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
University of Bonn
Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter.
Ritsumeikan University
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
University of Bonn
Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships.
University of Bonn
2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties.
Universita Degli Studi Di Bari
The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents.
University of South China
Inhibitors of ABCG2-mediated multidrug resistance: Lead generation through computer-aided drug design.
University of Perugia
Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Southern Medical University
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update.
National Institute of Pharmaceutical Education and Research-Hyderabad
9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
University of Bonn
Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters.
Key Laboratory of Technology of Drug Preparation (Zhengzhou University)
Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Dr. Harisingh Gour University
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
China Pharmaceutical University
Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Southern Medical University
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Federal University of Parana
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
Taipei Chang Gung Memorial Hospital
Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers.
Hong Kong Polytechnic University
Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).
Hong Kong Polytechnic University
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
Athenex
C@PA: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors.
University of Bonn
Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Claude Bernard University Lyon 1
Pyxinol bearing amino acid residues: Easily achievable and promising modulators of P-glycoprotein-mediated multidrug resistance.
Universities of Shandong
Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach.
University of Regensburg
Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
Rheinische Friedrich-Wilhelms-University Bonn
Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Rheinische Friedrich-Wilhelms-University of Bonn
Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Cnrs
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
University of Regensburg
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Pfizer
Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
Taipei Chang Gung Memorial Hospital
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
University of Bonn
Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein.
University of Turin
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
University of Bonn
Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Rheinische Friedrich-Wilhelms-University of Bonn
Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells.
University of Turin
Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
Univ. Grenoble Alpes
Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
University of Florence
Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
University of Florence
Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.
Rheinische Friedrich-Wilhelms-University of Bonn
Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
University of Bonn
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
Hong Kong Polytechnic University
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Takeda Pharmaceuticals International
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Bmssi Umr 5086 Cnrs/Universit£
Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.
Universidad Nacional De Colombia-Sede Bogot£
Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
Rheinische Friedrich-Wilhelms-Universit£T Bonn
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.
Csir - Indian Institute of Integrative Medicine
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
University of Bonn
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
University of Bonn
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.
Iteos Therapeutics
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
University of Bonn
Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
St. John'S University
Dual inhibitors of the human blood-brain barrier drug efflux transporters P-glycoprotein and ABCG2 based on the antiviral azidothymidine.
Purdue University
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
University of Bonn
Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
Bayer Pharma Aktiengesellschaft
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
Deuterx